Logo image of ALTS

ALT5 SIGMA CORP (ALTS) Stock Fundamental Analysis

NASDAQ:ALTS - US47089W1045 - Common Stock

6.85 USD
-0.3 (-4.2%)
Last: 8/27/2025, 8:00:01 PM
7.0197 USD
+0.17 (+2.48%)
After Hours: 8/27/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, ALTS scores 3 out of 10 in our fundamental rating. ALTS was compared to 193 industry peers in the Pharmaceuticals industry. ALTS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ALTS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ALTS had negative earnings in the past year.
ALTS had a positive operating cash flow in the past year.
In the past 5 years ALTS reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ALTS reported negative operating cash flow in multiple years.
ALTS Yearly Net Income VS EBIT VS OCF VS FCFALTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

1.2 Ratios

ALTS's Return On Assets of -8.92% is fine compared to the rest of the industry. ALTS outperforms 67.88% of its industry peers.
Looking at the Return On Equity, with a value of -27.10%, ALTS is in the better half of the industry, outperforming 61.66% of the companies in the same industry.
Industry RankSector Rank
ROA -8.92%
ROE -27.1%
ROIC N/A
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTS Yearly ROA, ROE, ROICALTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

ALTS has a Gross Margin of 49.24%. This is in the better half of the industry: ALTS outperforms 62.69% of its industry peers.
ALTS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ALTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
ALTS Yearly Profit, Operating, Gross MarginsALTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

3

2. Health

2.1 Basic Checks

ALTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALTS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALTS has more shares outstanding
The debt/assets ratio for ALTS is higher compared to a year ago.
ALTS Yearly Shares OutstandingALTS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALTS Yearly Total Debt VS Total AssetsALTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ALTS has an Altman-Z score of 8.78. This indicates that ALTS is financially healthy and has little risk of bankruptcy at the moment.
ALTS has a better Altman-Z score (8.78) than 85.49% of its industry peers.
The Debt to FCF ratio of ALTS is 18.18, which is on the high side as it means it would take ALTS, 18.18 years of fcf income to pay off all of its debts.
ALTS has a Debt to FCF ratio of 18.18. This is in the better half of the industry: ALTS outperforms 76.17% of its industry peers.
ALTS has a Debt/Equity ratio of 0.55. This is a neutral value indicating ALTS is somewhat dependend on debt financing.
ALTS's Debt to Equity ratio of 0.55 is on the low side compared to the rest of the industry. ALTS is outperformed by 61.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 18.18
Altman-Z 8.78
ROIC/WACCN/A
WACC9.96%
ALTS Yearly LT Debt VS Equity VS FCFALTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

ALTS has a Current Ratio of 0.83. This is a bad value and indicates that ALTS is not financially healthy enough and could expect problems in meeting its short term obligations.
ALTS has a worse Current ratio (0.83) than 85.49% of its industry peers.
ALTS has a Quick Ratio of 0.83. This is a bad value and indicates that ALTS is not financially healthy enough and could expect problems in meeting its short term obligations.
ALTS's Quick ratio of 0.83 is on the low side compared to the rest of the industry. ALTS is outperformed by 78.76% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.83
ALTS Yearly Current Assets VS Current LiabilitesALTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.79% over the past year.
The Revenue for ALTS have been decreasing by -18.62% on average. This is quite bad
EPS 1Y (TTM)88.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.87%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%N/A

3.2 Future

ALTS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.61% yearly.
The Revenue is expected to grow by 65.13% on average over the next years. This is a very strong growth
EPS Next Y-87.54%
EPS Next 2Y-4.52%
EPS Next 3Y28.61%
EPS Next 5YN/A
Revenue Next Year205.43%
Revenue Next 2Y125.77%
Revenue Next 3Y84.48%
Revenue Next 5Y65.13%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALTS Yearly Revenue VS EstimatesALTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
ALTS Yearly EPS VS EstimatesALTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALTS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTS Price Earnings VS Forward Price EarningsALTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALTS indicates a somewhat cheap valuation: ALTS is cheaper than 74.61% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 1079.54
EV/EBITDA N/A
ALTS Per share dataALTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as ALTS's earnings are expected to grow with 28.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.52%
EPS Next 3Y28.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALTS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALT5 SIGMA CORP

NASDAQ:ALTS (8/27/2025, 8:00:01 PM)

After market: 7.0197 +0.17 (+2.48%)

6.85

-0.3 (-4.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10
Inst Owners7.96%
Inst Owner Change0%
Ins Owners4.19%
Ins Owner Change0%
Market Cap839.88M
Analysts82.86
Price Target24.48 (257.37%)
Short Float %5.55%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-101.96%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)6.83%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 46.54
P/FCF 1079.54
P/OCF 1079.54
P/B 32.7
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)0.01
FCFY0.09%
OCF(TTM)0.01
OCFY0.09%
SpS0.15
BVpS0.21
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.92%
ROE -27.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.24%
FCFM 4.31%
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 18.18
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.83
Altman-Z 8.78
F-Score5
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.87%
EPS Next Y-87.54%
EPS Next 2Y-4.52%
EPS Next 3Y28.61%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%N/A
Revenue Next Year205.43%
Revenue Next 2Y125.77%
Revenue Next 3Y84.48%
Revenue Next 5Y65.13%
EBIT growth 1Y-45.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.41%
EBIT Next 3Y44.5%
EBIT Next 5Y44.66%
FCF growth 1Y119.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.92%
OCF growth 3YN/A
OCF growth 5YN/A